Search
Century Therapeutics Inc
IPSCAdd to Watchlist
1.450USD
+0.030+2.11%
Close 10-27 16:00（ET）
262.57MMarket Cap
LossP/E TTM
Century Therapeutics Inc (IPSC) Stock Price Target & Forecast
Analyst Rating
Based on 6 analysts giving stock ratings to Century Therapeutics Inc in the past month.
Buy
0 Strong Buy
5 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
5.120USD+260.56%
IPSC Analyst Recommendation Trends
In the current month, IPSC has received 5 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. IPSC average Analyst price target in the last month is 5.120.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
0
0
0
0
0
0
0
0
5
5
5
5
5
4
4
5
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6
6
6
6
6
5
5
6
IPSC Analyst Rating for Peer Comparison
Updated: Oct 27, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
Biontech SE
BNTX
4
12
8
0
0
24
Cytokinetics Inc
CYTK
5
16
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Financial Forecasting
Based on analysts' estimates, IPSC EPS is projected to reach -0.120 in FY2026Q3, following reported EPS of -0.168 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.28
-0.16
-0.11
-0.12
-0.13
Actual
-0.22
-0.11
-0.17
--
--
Surprise
+22.48%
+29.20%
-47.93%
--
--
FAQs
What is Century Therapeutics Inc's price target?
Analysts forecast that Century Therapeutics Inc's price target is USD 5.12, with the highest forecast at USD 8.00 and the lowest forecast at USD 2.00.
How have Century Therapeutics IncIPSC's recent earnings per share performed?
The market expectation was USD -0.17, while Century Therapeutics IncIPSC's earnings per share (EPS) for the previous quarter was USD -0.11. EPS for the next quarter is expected at USD -0.12.
What is the analyst rating for Century Therapeutics Inc?
Based on the ratings of Century Therapeutics Inc's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.